In this article, we will take a look at some of the best fast money stocks to buy now.
In this fast-paced world, most people have become impatient. Everyone is drawn to whatever delivers quick results, whether it be fast fame or fast money. When it comes to investing, some stocks are built for the long haul, while others return quickly.
That being said, investing in such stocks doesn’t necessarily imply jumping in the dark; instead, some stocks are designed in a way that drives returns through market volatility. From small-cap companies awaiting FDA approval or benefitting from successful trials to undervalued mid-caps, each is seeking its plot twist.
As stated in Morgan Stanley’s “Stocks’ Momentum Masks Risks,”
Consider that while the S&P 500 rose about 23% in 2024, the stocks with the strongest 12-month momentum (i.e., those rising the fastest for that time frame) were up an extraordinary 58% for the year, outperforming all other “factors,” including growth- and value-oriented equities, by at least 38 percentage points.
Our methodology:
Using Finviz’s stock screener, we have filtered for stocks trading under $50, exhibiting a relative volume of over 1.5 and a month-to-date performance of 50% or more as of September 28, 2025. These are then ranked in ascending order according to their upside potential, calculated using one-year price targets by Yahoo Finance.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11. Dragonfly Energy Holdings Corp. (NASDAQ:DFLI)
Upside Potential as of September 29, 2025: 50.25%
On Friday, Wall Street Zen upgraded Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) to hold. This revision can be attributed to the company’s OEM collaboration with Ember Recreational Vehicles, which was announced on September 9, 2025. Under the contract, Ember’s 2026 Overland Series will feature Battle Born Batteries as part of the new Max Solar Package.
A testament to the many years-long partnership with Ember, the new standard Max Solar Package will enable Ember’s customers to benefit from a complete energy system for prolonged off-grid adventures, including 3.5 to 7 kWh of LiFePO₄ batteries and 1,200 watts of rooftop solar.
Developed to support a wide range of needs, the power system will include Battle Born GC3 deep-cycle batteries to enhance the overall experience. As stated by Wade Seaburg, Chief Commercial Officer of Dragonfly Energy Holdings Corp. (NASDAQ:DFLI),
By making Battle Born Batteries standard in the Overland Series, we believe Ember is giving its customers the energy storage capacity they need to take full advantage of their solar power. That means longer run times, the ability to power real appliances, and a more confident experience off the grid.
Dragonfly Energy Holdings Corp. (NASDAQ:DFLI), headquartered in Reno, Nevada, is a manufacturer and seller of deep-cycle lithium-ion batteries for vehicles, vessels, and industrial and energy storage markets. With a commitment to providing sustainable power solutions, the company operates through two segments: direct-to-consumers and original equipment manufacturers.
10. Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Upside Potential as of September 29, 2025: 57.35%
Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price target of $100, implying a potential upside of nearly 172% from the current price. This optimism is driven by the company’s lead candidate, Claseprubart, which is what they refer to as a “best-in-class complement inhibitor.”
The research firm believes that Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is in a good position to enhance treatment standards in three autoimmune conditions undergoing clinical testing: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), with each of these representing a market of up to $2 billion.
While highlighting the company’s latest Phase 2 data in gMG, Clear Street noted the prospects surrounding CIDP and MMN, with data updates projected for the latter half of next year. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has already delivered a year-to-date return of 68.39%, outperforming the market average by an impressive 55.43%.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a New York-based clinical-stage biotechnology company offering solutions for patients living with severe autoimmune and inflammatory diseases. Founded in 2019, the company focuses on enhancing the selectivity of complement therapeutics.
9. PepGen Inc. (NASDAQ:PEPG)
Upside Potential as of September 29, 2025: 75.76%
H.C. Wainwright has reaffirmed its ‘Buy’ rating on PepGen Inc. (NASDAQ:PEPG), while increasing the price target to $12.00 from $8.00, implying a surge of nearly 135%. This optimism stems from the company’s 53.7% mean splicing correction at 15 mg/kg report in its FREEDOM single-dose study for DM1 patients, showcasing the highest level disclosed in DM1 patients till now.
The research firm noted that this nearly 54% splicing correction establishes a new standard, pointing to the high chances of repeat dosing delivering significant functional advancements. While expanding the therapeutic window for PepGen Inc. (NASDAQ:PEPG) to a safe and efficacious dose, this could return massively to real health improvements.
Considering the company’s financials, PepGen Inc. (NASDAQ:PEPG) delivered a return of 34.04% in contrast to the market’s average of 13.10%, reflecting an impressive outperformance of nearly 21%.
PepGen Inc. (NASDAQ:PEPG), headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Incepted in 2018, the company offers PGN-EDO51, PGN-EDODM1, and PGN-EDO53.
8. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Upside Potential as of September 29, 2025: 79.41%
Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), while raising the price target to $143 from $86, implying an upside potential of over 200% from the current levels. This confidence follows the company’s successful approval of Palsonify.
The firm notes that Palsonify, an oral SST2 agonist designed for acromegalic adults who aren’t fit for surgery, receives a broad label without any safety red flags, highlighting not only the rapidity of response but also improvement in symptom severity. While JMP had a price guidance of $125,000, the drug is sold at a price of $290,000 annually, which is significantly higher than the projected amount.
That’s not it. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is seizing every possible opportunity for expansion. This includes a Phase 3 study for carcinoid syndrome, along with two Phase 3 trials for atumelnant in congenital adrenal hyperplasia, planned for the end of the year.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a California-based clinical-stage pharmaceutical company specializing in novel therapeutics for rare endocrine diseases and endocrine-related tumors. Incorporated in 2008, the company is committed to improving the lives of its patients.
7. Rapport Therapeutics, Inc. (NASDAQ:RAPP)
Upside Potential as of September 29, 2025: 84.23%
Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial for RAP-219 in refractory focal epilepsy.
Keeping in view the year-to-date returns posted by Rapport Therapeutics, Inc. (NASDAQ:RAPP), the company outperformed the market by an impressive 45%. What’s even more interesting about the company is its recent data, which is defined by a large market of 1.8 million patients in the U.S., with 40% of them continuing to be treatment resistant.
During the presentation at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, the leadership expressed enthusiasm about its RAP-219, which they view as a multibillion-dollar market opportunity. As stated by the CEO, Abraham Ceesay,
And that’s really defined by a novel MOA with RAP-219; two, efficacy that we think is really best-in-class from what we’ve seen from our proof-of-concept study, a drug that’s generally well tolerated and consistent with precision biology.
Rapport Therapeutics, Inc. (NASDAQ:RAPP), headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company that develops medicines for individuals living with central nervous system (CNS) disorders. Incorporated in 2022, the company is committed to developing therapies with enhanced efficacy.
6. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
Upside Potential as of September 29, 2025: 117.07%
During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 13,182 shares of the company’s stock. According to the latest filing with the SEC, the firm’s investment in the company is approximately $59,000.
There are many advocates for Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), and it comes as no surprise. The company has managed to strike another deal with Novartis, which involves both companies developing molecular glue degraders for immune-mediated disorders. This is yet another major highlight as it brings forth $120 million in proceeds, along with the potential to generate $5.7 billion in milestone payments.
If that weren’t already a strong case, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been awarded IND clearance from the FDA to accelerate MRT-8102, a second molecular glue degrader. As long as the company executes its initiatives successfully, we have a good reason to believe in the potential for this stock to be rewarding.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a Massachusetts-based clinical-stage biotechnology company developing novel small-molecule precision medicines. Incepted in 2019, the company maintains a strategic partnership and licensing agreement with F. Hoffmann-La Roche Ltd.
5. Immuneering Corporation (NASDAQ:IMRX)
Upside Potential as of September 29, 2025: 139.88%
Analysts at Mizuho have reaffirmed their ‘Outperform’ rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying a surge of about 43%. This optimism stems from the company’s positive clinical trial outcome for its lead drug candidate.
On Wednesday, Immuneering Corporation (NASDAQ:IMRX) reported modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi), together with updated gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The data, collected from 34 patients, reflected overall survival and progression-free survival results that not only surpassed the traditional standard-of-care treatments, but also the research firm’s own expectations.
What keeps the investor’s interest is the company’s atebimetinib, which has the potential to become a top-tier treatment for first-line pancreatic cancer patients. With the results demonstrating enhanced durability in contrast to the previous 6-month data update from June, we have a good reason to believe in the prospects of the drug, and ultimately Immuneering Corporation (NASDAQ:IMRX).
Immuneering Corporation (NASDAQ:IMRX) is a Massachusetts-based clinical-stage oncology company specializing in treatments targeting broad populations of cancer patients. Founded in 2008, the company is committed to developing innovative medicines.
4. Datavault AI Inc. (NASDAQ:DVLT)
Upside Potential as of September 29, 2025: 157.45%
On Friday, Datavault AI Inc. (NASDAQ:DVLT) announced an update to its agreement with International Business Machines Corporation (IBM), modifying the payment schedule for software subscription licenses and expediting the program’s start date.
Under the amended contract, Datavault AI Inc. (NASDAQ:DVLT) has agreed to pay IBM $2,500,000 toward previously scheduled program payments. With $3,296,183 due to be paid on December 23, 2025, eight payments of $2,183,676 each will be settled quarterly from March 2026 through December 2027.
In addition to this, the amendment also accelerates the initiation of the one-year committed term for the “Fixed Quantity Subscription License Programs” to September 30, 2025, reflecting a shift of two months ahead from the previous schedule. Projects like this underscore the company’s presence in the market while hinting at the step towards recovery. To say the least, Datavault AI Inc. (NASDAQ:DVLT) is a speculative yet potentially lucrative gem.
Datavault AI Inc. (NASDAQ:DVLT) is an Oregon-based data sciences technology company managing data management platforms. Incorporated in 2010, the company maintains a solid presence in North America, the Asia Pacific, Europe, and internationally.
3. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Upside Potential as of September 29, 2025: 160.58%
During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 and an ownership of nearly 1.08%.
Oppenheimer is among the many research firms bullish on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). After the company’s collaboration with Pfizer, aiming to test Pfizer’s next-generation CDK4-selective drug atirmociclib in combination with Olema’s palazestrant, the research firm issued an ‘Outperform’ rating on the stock, along with a price target of $22.
This potential upside of over 130% is no accident, as many believe Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is strategically well-positioned with two key players in HR-positive breast cancer, with the company’s current palazestrant and ribociclib combination study with Novartis.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a California-based clinical-stage biopharmaceutical company developing and commercializing therapies for women’s cancers. Incorporated in 2006, the company is dedicated to impacting breast cancer.
2. Annexon, Inc. (NASDAQ:ANNX)
Upside Potential as of September 29, 2025: 274.8%
During the first quarter, Nuveen LLC acquired a new position in Annexon, Inc. (NASDAQ:ANNX) through the purchase of 23,491 shares of the company’s stock. According to a recent disclosure with the SEC, the global asset firm now owns 0.14% of the company, translating to an investment of approximately $666,000.
What makes Annexon, Inc. (NASDAQ:ANNX) truly exciting is its one-of-a-kind programs. If we consider the Guillain-Barré syndrome, it’s the only program in this space in the last 50 years. This showcases the company’s position in unprecedented data and its efforts to improve the lives of patients with this debilitating disease.
If that wasn’t impressive enough, Annexon, Inc. (NASDAQ:ANNX) is leading a geographic atrophy program considered the sole vision-sparing program in the world. Having received the prime designation, this venture is set to drive the company’s future.
Annexon, Inc. (NASDAQ:ANNX) is a California-based clinical-stage biopharmaceutical company providing solutions for inflammatory-related diseases. Incorporated in 2011, the company is committed to putting an end to classical complement-driven neuroinflammation.
1. Nvni Group Limited (NASDAQ:NVNI)
Upside Potential as of September 29, 2025: 401.86%
On September 24, 2025, Nvni Group Limited (NASDAQ:NVNI) unveiled the NuviniAI Index, a tool designed to examine AI adoption in institutions. This is an attempt to drive internal portfolio transition and improve overall M&A qualification. Two days later, the company announced early results from its NuviniAI Lab, which has shifted its development teams to AI-driven platforms, highlighting increased operational efficiencies and driving scalable AI innovation.
With no underlying surprises, this initiative positions Nvni Group Limited (NASDAQ:NVNI) as a best-in-class agency on AI maturity in Latin America, offering both a strategic framework for portfolio companies and acquisition opportunities. We already know that Nvni Group Limited (NASDAQ:NVNI) performed quite well in the past year. In contrast to the market’s rate of 15.93%, the company delivered an impressive 58.62%.
The company’s Chief Executive Officer, Pierre Schurmann, is expected to participate in the keynote presentation called “LatAm Giants Mastering Expansion: The Global Playbook,” scheduled for September 30, 2025, at Brazil Investment Week in London, UK.
Nvni Group Limited (NASDAQ:NVNI) is a Brazilian company providing a business-to-business SaaS platform. Founded by Pierre Schurmann and Luiz Busnello, the company offers cloud solutions.
While we acknowledge the potential of NVNI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVNI and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
